drugset / Trial / NCT00024024

BMS-275291 in Treating Patients With HIV-Related Kaposi's Sarcoma

NCT00024024

Phase 1/2 Completed 59 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

Phase I/II trial to study the effectiveness of BMS-275291 in treating patients who have HIV-related Kaposi's sarcoma. Drugs such as BMS-275291 may stop the growth of Kaposi's sarcoma by stopping blood flow to the tumor.

Timeline

Start
2001-08
Primary completion
2003-08
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject rebimastat Small molecule 600 mg Oral
Subject rebimastat Small molecule 1200 mg Oral

Indications